SCHEMBL590109

SCHEMBL590109

NCc1csc(-c2ccccc2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.62
DRD2 P14416 2/20 0.57
DRD4 P21917 2/20 0.57
DRD3 P35462 2/20 0.57
HPGD P15428 3/20 0.53
RAB9A P51151 6/20 0.51
LMNA P02545 2/20 0.51
MAPT P10636 3/20 0.50
NPC1 O15118 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PRNP P04156 1/20 0.49
KMT2A Q03164 2/20 0.49
AR P10275 1/20 0.49
MEN1 O00255 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
GAA P10253 1/20 0.48
ATM Q13315 1/20 0.48
GFER P55789 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14736420 0.85 LMNA (0.56) KDM4EDRD2DRD4DRD3HPGD
SCHEMBL28146103 0.85 RAB9A (0.51) KDM4EDRD2DRD4DRD3HPGD
Hydrochloric Acid SCHEMBL17261485 0.84 LMNA (0.55) KDM4EDRD2DRD4DRD3HPGD
Hydrochloric Acid SCHEMBL17261571 0.84 LMNA (0.55) KDM4EDRD2DRD4DRD3HPGD
SCHEMBL3820711 0.81 GFER (0.72) KDM4ERAB9ALMNAMAPTNPC1
SCHEMBL28938187 0.81 LMNA (0.52) KDM4ERAB9ALMNAMAPTNPC1
SCHEMBL8091022 0.81 LMNA (0.52) KDM4EDRD2DRD4DRD3HPGD
SCHEMBL10031024 0.81 LMNA (0.59) KDM4EDRD2DRD4DRD3HPGD
SCHEMBL104385 0.81 DRD2 (0.57) KDM4EDRD2DRD4DRD3HPGD
SCHEMBL3368273 0.81 DRD2 (0.57) KDM4EDRD2DRD4DRD3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2091951-B1 PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON INC (US) 2018-02-28 EP claimed
US-7601716-B2 Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors CEPHALON, INC. (US) 2009-10-13 US claimed
EP-2091951-A2 PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2009-08-26 EP claimed
US-20080032972-A1 Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors CEPHALON, INC. (US) 2008-02-07 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
WO-2007130468-A2 PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2007-11-15 WO claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
US-11737463-B2 Pyridine and pyrazine compounds BASF SE (DE) 2023-08-29 US disclosed
EP-3380471-B1 TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES AS COMT INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS LIEBER INST INC DBA LIEBER INST FOR BRAIN DEVELOPMENT (US) 2021-09-08 EP disclosed
US-20210145002-A1 PYRIDINE AND PYRAZINE COMPOUNDS BASF SE (DE) 2021-05-20 US disclosed
US-20210139479-A1 COMT Inhibiting Methods and Compositions LIEBER INST INC (US) 2021-05-13 US disclosed
US-20200354321-A1 NEW PYRIDINE CARBOXAMIDES BASF SE (DE) 2020-11-12 US disclosed
US-10696634-B2 Pyridine compounds as fungicides BASF SE (DE) 2020-06-30 US disclosed
WO-2003057205-A2 COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-07-17 WO disclosed
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-04-17 US disclosed
WO-2003004020-A1 HETEROARYL CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-01-16 WO disclosed
US-6380187-B2 FUNGICIDES YU DINGWEI TIM (US) 2002-04-30 US disclosed
US-6281217-B2 ANTIFUNGAL ACTIVITY AGAINST A VARIETY OF FUNGI INCLUDING STRAINS WHICH HAVE PROVEN TO BE RESISTANT TO TREATMENT WITH KNOWN ANTIFUNGAL AGENTS SUCH AS FLUCONAZOLE. YU DINGWEI TIM (US) 2001-08-28 US disclosed
US-6277873-B1 CONTROLLING DRUG RESISTANT FUNGI YU DINGWEI TIM (US) 2001-08-21 US disclosed
CN-1276790-A Carboxamidothiazole derivs., preparation, pharmaceutical composition contg. them SANOFI SA (FR) 2000-12-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11737463-B2 Pyridine and pyrazine compounds NDUFS5, IL5, NDUFS4 KDM4E 1933/4885DRD2 2830/4885DRD4 1405/4885
US-20210145002-A1 PYRIDINE AND PYRAZINE COMPOUNDS NDUFS5, IL5, NDUFS4 KDM4E 1933/4885DRD2 2830/4885DRD4 1405/4885
US-20200354321-A1 NEW PYRIDINE CARBOXAMIDES COX4I1, NQO2, NDUFS5 KDM4E 509/4885DRD2 2209/4885DRD4 1361/4885
US-20210139479-A1 COMT Inhibiting Methods and Compositions COMT, PNMT, HNMT KDM4E 283/4885DRD2 263/4885DRD4 340/4885
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL KDM4E 3446/4885DRD2 3101/4885DRD4 2219/4885
US-10696634-B2 Pyridine compounds as fungicides CYP4X1, CYP1A1, CYP4B1 KDM4E 360/4885DRD2 1699/4885DRD4 615/4885
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions MTTP, CETP, CES1 KDM4E 1812/4885DRD2 4262/4885DRD4 3954/4885
US-20080032972-A1 Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors ALK, MET, RET KDM4E 594/4885DRD2 1872/4885DRD4 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.